Innovate or Be Left Behind: A Path to Prospective External Control Arms for Accelerated Oncology Drug Development
Journal of Clinical Oncology · 05.08.2026
DOI: 10.1200/jco-26-01081 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Oncology, online erschienen am 05.08.2026. Verfasst von Stephen M Hahn und 5 weiteren Autor:innen. Beteiligte Einrichtung: Nucleus RadioPharma, Davidson, NC. Die Arbeit nennt 39 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Autor:innen und Institutionen
- Nucleus RadioPharma, Davidson, NC.
- Lineberger Comprehensive Cancer Center, The University of North Carolina School of Medicine, Chapel Hill, NC.
- N-Power Medicine Inc, Redwood City, CA.
- AdventHealth Cancer Institute, Orlando, FL.
ORCID-Profile: Norman E Sharpless, Mark Lee, Mark A Socinski
Zitieren
APA
Hahn, S. M., Sharpless, N. E., Svedman, C., Capra, W. B., Lee, M., & Socinski, M. A. (2026). Innovate or Be Left Behind: A Path to Prospective External Control Arms for Accelerated Oncology Drug Development. Journal of Clinical Oncology. https://doi.org/10.1200/jco-26-01081
Vancouver
Hahn SM, Sharpless NE, Svedman C, Capra WB, Lee M, Socinski MA. Innovate or Be Left Behind: A Path to Prospective External Control Arms for Accelerated Oncology Drug Development. Journal of Clinical Oncology. 2026. doi:10.1200/jco-26-01081
BibTeX
@article{Hahn2026,
author = {Hahn, Stephen M and Sharpless, Norman E and Svedman, Christer and Capra, William B and Lee, Mark and Socinski, Mark A},
title = {Innovate or Be Left Behind: A Path to Prospective External Control Arms for Accelerated Oncology Drug Development},
journal = {Journal of Clinical Oncology},
year = {2026},
doi = {10.1200/jco-26-01081}
}
EUVIMED